IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.918
AS - Asia 5.317
EU - Europa 4.424
SA - Sud America 684
AF - Africa 95
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 17.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.733
CN - Cina 2.645
SG - Singapore 1.292
IE - Irlanda 1.099
HK - Hong Kong 759
RU - Federazione Russa 580
BR - Brasile 552
FI - Finlandia 491
IT - Italia 471
DE - Germania 470
UA - Ucraina 416
GB - Regno Unito 232
SE - Svezia 225
FR - Francia 217
VN - Vietnam 189
IN - India 113
CA - Canada 105
JP - Giappone 60
AR - Argentina 53
MX - Messico 45
TR - Turchia 45
PL - Polonia 42
BD - Bangladesh 39
ZA - Sudafrica 35
NL - Olanda 31
BE - Belgio 30
ES - Italia 24
ID - Indonesia 23
IQ - Iraq 22
AT - Austria 17
EC - Ecuador 16
AU - Australia 14
CO - Colombia 14
IR - Iran 14
LT - Lituania 14
PK - Pakistan 12
VE - Venezuela 12
MA - Marocco 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
JO - Giordania 10
KR - Corea 10
PY - Paraguay 10
CZ - Repubblica Ceca 9
JM - Giamaica 9
KE - Kenya 9
UZ - Uzbekistan 9
EU - Europa 8
AZ - Azerbaigian 7
MD - Moldavia 7
TN - Tunisia 7
MY - Malesia 6
PA - Panama 6
RO - Romania 6
SN - Senegal 6
UY - Uruguay 6
DK - Danimarca 5
EG - Egitto 5
IL - Israele 5
NP - Nepal 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
CH - Svizzera 4
CU - Cuba 4
GR - Grecia 4
LV - Lettonia 4
BO - Bolivia 3
CI - Costa d'Avorio 3
DZ - Algeria 3
GY - Guiana 3
HU - Ungheria 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
NG - Nigeria 3
SV - El Salvador 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
NI - Nicaragua 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
Totale 17.441
Salva come PNG Salva come JPEG
Città #
Dublin 1.096
Chandler 1.019
Hong Kong 758
Dallas 674
Singapore 627
Jacksonville 577
Ashburn 567
Nanjing 523
Beijing 467
Boardman 357
Los Angeles 228
Princeton 220
Lawrence 202
Nanchang 201
Wilmington 184
New York 179
Hebei 172
Helsinki 154
Changsha 143
Medford 143
Shenyang 138
Munich 132
Ann Arbor 130
Jiaxing 123
Shanghai 106
Tianjin 104
Buffalo 103
Redondo Beach 102
Moscow 99
Hangzhou 77
Ho Chi Minh City 75
Pavia 70
Milan 69
São Paulo 61
Tokyo 54
Seattle 52
Turku 52
The Dalles 46
Santa Clara 44
Falkenstein 42
Pune 41
San Francisco 39
Columbus 37
Hanoi 36
Stockholm 36
Woodbridge 36
Falls Church 35
Warsaw 34
Norwalk 33
Montreal 31
Chennai 30
Orem 30
Toronto 30
Brussels 28
Chicago 27
Brooklyn 26
Nuremberg 26
Guangzhou 25
Johannesburg 24
Washington 24
Ankara 22
Verona 22
London 20
Poplar 20
Zhengzhou 20
Belo Horizonte 19
Denver 19
Manchester 19
Paris 19
Atlanta 17
Frankfurt am Main 17
Houston 17
Fairfield 16
Rome 15
Boston 14
Brescia 13
Des Moines 13
Mexico City 13
Jinan 12
Phoenix 12
Brasília 11
Xi'an 11
Amsterdam 10
Auburn Hills 10
Calgary 10
Jakarta 10
Kunming 10
Lanzhou 10
Renton 10
Shijiazhuang 10
Chongqing 9
Curitiba 9
Elk Grove Village 9
Seoul 9
Amman 8
Baghdad 8
Council Bluffs 8
Dhaka 8
Ningbo 8
Secaucus 8
Totale 11.323
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 184
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 162
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 162
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 143
An insidious presentation of splenic marginal zone lymphoma 137
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 136
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 135
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 128
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 123
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 122
Blast phase of essential thrombocythemia: A single center study. 121
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 121
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 120
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 118
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 113
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 112
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 110
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 109
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 108
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 108
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 107
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 107
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 105
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 104
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 102
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 102
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 102
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 101
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders 101
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 98
A young woman with microcytic anemia and hypertransaminasemia 98
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 97
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 96
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 96
Everolimus in diffuse large B-cell lymphomas 95
A paraumbilical lymphomatous mass 93
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice 92
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 91
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 91
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 90
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 90
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 90
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 90
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 90
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 89
Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas 89
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 87
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 87
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 86
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 86
Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma 85
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 85
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 85
Transient response of myeloma clone to pamidronate therapy 85
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 84
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 84
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 84
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 84
Antiviral therapies for managing viral hepatitis in lymphoma patients 84
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 84
Diagnosis and management of prefibrotic myelofibrosis. 84
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 83
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 83
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 83
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 82
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 82
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 82
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 82
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center 82
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 82
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 81
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network 81
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 80
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. 80
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network 80
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 79
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 79
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 79
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 79
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 79
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 78
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 78
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. 78
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins 78
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 77
Role of the molecular staging and response in the management of follicular lymphoma patients 77
Splenic marginal zone lymphoma: hydra with many heads? 77
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 77
Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome 77
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 77
The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. 77
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 76
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. 76
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 75
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 75
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities. 75
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. 75
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 74
Overview on the management of non-gastric MALT lymphomas 74
Totale 9.426
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.705
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021731 0 0 0 0 0 170 14 177 107 123 115 25
2021/2022971 22 5 19 15 38 55 19 56 53 40 141 508
2022/20232.990 277 196 21 239 279 318 27 177 1.257 28 111 60
2023/20241.404 147 234 60 97 107 395 34 84 12 53 74 107
2024/20253.787 116 269 74 88 78 233 349 242 846 136 466 890
2025/20264.559 635 660 986 992 952 334 0 0 0 0 0 0
Totale 18.077